Hip and knee replacement
Conditions
Interventions
rivaroxaban group:Rivaroxaban was used for anticoagulation during perioperative period
low molecular heparin group:Low molecular weight heparin (LMWH) was used in perioperative anticoagulation
Sponsors
Department of Orthopaedics, First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) patients undergoing primary total hip and knee arthroplasty in our department; (2) Aged at least 18 years old; (3) preoperative color doppler ultrasound examination of DVT(-) in both lower limbs; (4) platelet count 100-300 X 10^9/L; (5) the postoperative application of rivaroxaban anticoagulation therapy; (6) patients' informed consent.
Exclusion criteria
Exclusion criteria: 1. preoperative color doppler examination of lower extremity DVT(+), or venous valve dysfunction of lower extremity; 2. have a history of lower limb venous thrombosis or pulmonary embolism; 3. preoperative coagulation dysfunction, contraindication of anticoagulation therapy, or high risk of bleeding (platelet count <100 X 10^9/ l-prothrombin activity <60%), or active bleeding, or taking anticoagulant drugs cannot be stopped; 4. revision surgery or surgical joint infection (specific or non-specific); 5. patients with contraindications specified in the directions of rivaroxaban: patients who are allergic to rivaroxaban or any excipients in the tablets; Liver disease patients with clinically relevant risk of bleeding; Pregnant and lactating women; 6. the patient refused to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of anti - factor Xa activity;thromboelastogram;Blood routine, liver and kidney function, blood coagulation;ecchymosis; | — |
Countries
China
Contacts
Public ContactWei Huang
First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed